Brumfitt W, Hamilton-Miller J M
Department of Medical Microbiology, Royal Free Hospital Medical School, Hampstead, London, UK.
J Antimicrob Chemother. 1988 Jun;21(6):711-20. doi: 10.1093/jac/21.6.711.
DuP 105 and 721, synthetic antibiotics belonging to a totally novel chemical class (oxazolidinones), have been found to be active in vitro against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. DuP 721 had geometric mean MICs ranging from 1.1 to 16 mg/l against 167 strains of Staph. aureus, Staph. epidermidis, Staph. saprophyticus, streptococci of Groups A, B and D and diphtheroids. DuP 105 was between 1.5 and eight-fold less active. Bacteroides fragilis strains were also susceptible to the DuP compounds (mean MICs being 8.3 and 14.9 mg/l for DuP 721 and 105, respectively), but other Gram-negative species and yeasts were not inhibited by concentrations in excess of 100 mg/l. Both compounds had a predominantly bacteriostatic action. No primary resistance was found, and the incidence of resistant variants in 105 strains tested was less than 1 per 10(8) bacteria.
DuP 105和721是属于全新化学类别（恶唑烷酮类）的合成抗生素，已发现它们在体外对多种革兰氏阳性菌具有活性，包括耐甲氧西林金黄色葡萄球菌。DuP 721对167株金黄色葡萄球菌、表皮葡萄球菌、腐生葡萄球菌、A、B和D组链球菌以及类白喉杆菌的几何平均最低抑菌浓度（MIC）范围为1.1至16毫克/升。DuP 105的活性比其低1.5至8倍。脆弱拟杆菌菌株也对DuP化合物敏感（DuP 721和105的平均MIC分别为8.3和14.9毫克/升），但其他革兰氏阴性菌和酵母在浓度超过100毫克/升时不受抑制。这两种化合物主要具有抑菌作用。未发现原发性耐药，在测试的105株菌株中，耐药变体的发生率低于每10⁸个细菌1株。
